Observational studyBMC anesthesiology2026
Impact of immunosuppression on the incidence of ventilator-associated events: an observational study.
Observational study in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCritically ill immunocompromised patients requiring mechanical ventilation (MV) may be particularly vulnerable to ventilator-associated events (VAE), yet the impact of baseline immunosuppression on VAE incidence remains unclear.
methodsWe conducted a secondary analysis of a cohort of adults requiring MV for ≥4 days in two ICUs of a tertiary hospital in Moscow, Russia. Using competing-risk regression, we compared the 30-day incidence of VAE between immunocompromised and non-immunocompromised patients. We then evaluated the association between VAE and 30-day ICU mortality among immunocompromised patients using Cox regression.
resultsOf 269 patients, 122 (45.4%) had baseline immunosuppression. The incidence of any VAE was higher in immunocompromised patients, though the estimate was imprecise (adjusted subhazard ratio [aSHR] 1.64; 95% CI 0.82–3.30); for infection-related ventilator-associated complications (IVAC), the estimate suggested a more than twofold increased hazard, but with considerable uncertainty (aSHR 2.22; 95% CI 0.85–5.78). In patients with immunosuppression, IVAC were associated with increased mortality (adjusted hazard ratio 2.38; 95% CI 1.16–4.89).
conclusionDespite a higher estimated incidence of VAE in immunocompromised patients, we could not establish a clear association between baseline immunosuppression and VAE risk. IVAC were associated with increased mortality in immunocompromised patients, although this finding should be considered exploratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.